Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 5/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18974603 | 0.97 | SCN9A (0.40) | RORCSCN9ATAS2R14HCRTR2STAT3 | |
| SCHEMBL18974653 | 0.94 | SCN9A (0.38) | RORCSCN9ATAS2R14HCRTR2STAT3 | |
| SCHEMBL20530887 | 0.93 | SIRT2 (0.39) | RORCSCN9ATAS2R14HCRTR2STAT3 | |
| SCHEMBL18975059 | 0.93 | NSD2 (0.41) | RORCSCN9AKDM1AMYC | |
| SCHEMBL18974805 | 0.93 | CYP19A1 (0.40) | RORCSCN9ATAS2R14MYC | |
| SCHEMBL18974614 | 0.93 | POLB (0.40) | SCN9AKDM1AMYC | |
| SCHEMBL18974599 | 0.93 | LPAR1 (0.40) | RORCSCN9ATAS2R14MYCFNTA | |
| SCHEMBL18974173 | 0.92 | POLB (0.39) | RORCSCN9AKDM1AMYCFNTA | |
| SCHEMBL18975063 | 0.91 | SCN9A (0.36) | RORCSCN9ATAS2R14BCHEACHE | |
| SCHEMBL18974850 | 0.91 | SCN9A (0.42) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-10689354-B2 | Aminoazole derivative | TEIJIN PHARMA LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-10689354-B2 | Aminoazole derivative | TEIJIN PHARMA LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| EP-3388425-A1 | AMINOAZOLE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017099237-A1 | AMINOAZOLE DERIVATIVE | 帝人ファーマ株式会社 | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689354-B2 | Aminoazole derivative | AR, NR3C2, NR5A1 | RORC 163/4885SCN9A 930/4885TAS2R14 112/4885 |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | AR, NR3C2, NR5A1 | RORC 163/4885SCN9A 930/4885TAS2R14 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.